User:Mr. Ibrahem/Deucravacitinib

Mr. Ibrahem/Deucravacitinib
Clinical data
Pronunciation	/duːˌkrævəˈsɪtɪnɪb/; doo-KRA-və-SI-ti-nib
Trade names	Sotyktu
Other names	BMS-986165
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
Drug class	TYK2 inhibitor
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	99%
Protein binding	82–90%
Metabolism	Liver (primarily CYP1A2)
Metabolites	BMT-153261 (active)
Elimination half-life	10 hours
Excretion	Feces, urine
Identifiers
	IUPAC name 6-(Cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide;
Chemical and physical data
Formula	C20H22N8O3
Molar mass	422.449 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4;
	InChI InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3; Key:BZZKEPGENYLQSC-FIBGUPNXSA-N;

Deucravacitinib, sold under the brand name Sotyktu, is a medication used to treat moderate to severe plaque psoriasis.^[1] It should not be used with other strong immunosuppressants.^[1] It is take by mouth.^[1]

Common side effects include upper respiratory infections, herpes simplex, folliculitis, and acne.^[1] Other side effects may include allergic reactions, infection, cancer, and muscle breakdown.^[1] Use in pregnancy is of unclear safety.^[1] Use is not recommended in those with significant liver problems.^[1] It is a TYK2 inhibitor.^[1]

Deucravacitinib was approved for medical use in the United States in 2022.^[1] As of 2022 it is not approved in Europe or the United Kingdom.^[2] In the United States it costs about 6,200 USD per month.^[2]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
^ ^a ^b "Deucravacitinib". SPS - Specialist Pharmacy Service. 1 November 2018. Archived from the original on 29 June 2022. Retrieved 13 December 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.

[SPS2022-2] "Deucravacitinib". SPS - Specialist Pharmacy Service. 1 November 2018. Archived from the original on 29 June 2022. Retrieved 13 December 2022.

[1]

[2]